Please assess the completion status of the following clinical trial:

Trial Title: Study Comparing The Effect On Disease Activity When Reducing Or Discontinuing Etanercept In Subjects With RA

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion criteria:~* Subject has a current DAS28 equal to or less than 3.2.~* Subject is currently receiving treatment with etanercept, either 25 mg twice weekly or 50 mg once weekly, for a minimum of 14 months at baseline~* Subject is currently receiving oral, sc or intramuscular methotrexate once weekly, 7.5 mg/week to 25 mg/week and at a stable dose for a minimum of 4 months at baseline.~Exclusion Criteria:~* Subject has earlier had an attempt of discontinuing etanercept for reasons of remission or low disease activity state.~* Subject has received any disease-modifying anti-rheumatic drug, other than methotrexate, within one month before baseline.~* Subject has had a dose of prednisone (or equivalent) \>7.5 mg/day or has received intra-articular, intravenous, intramuscular, or subcutaneous corticosteroid within one month of baseline.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): 50mg once weekly + methotrexate
- 2 (Type: ACTIVE_COMPARATOR): 25mg once weekly + methotrexate
- 3 (Type: PLACEBO_COMPARATOR): once weekly + methotrexate

Based on this trial design, predict the completion outcome and termination type (if applicable).